爱尚大众

Wuhan Dazhong Dental Medical Co., Ltd.
武漢大眾口腔醫療股份有限公司

(A joint stock company with limited liability incorporated in the People's Republic of China)

(Stock Code: 2651)

ANNOUNCEMENT
(1) PROPOSED CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR
(2) ADJUSTMENT OF MEMBERS OF COMMITTEES UNDER THE BOARD
(3) PROPOSED CANCELLATION OF THE BOARD OF SUPERVISORS AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND CERTAIN RULES
AND
(4) CLOSURE OF REGISTER OF MEMBERS

PROPOSED CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Wuhan Dazhong Dental Medical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") received the resignation letter from Ms. Wang Taosha ("**Ms. Wang**"), an independent non-executive Director of the Company. Ms. Wang has resigned as an independent non-executive Director of the fourth session of the Board, a member of the audit committee under the Board (the "**Audit Committee**") and a member of the nomination committee under the Board (the "**Nomination Committee**") due to other work commitments. Ms. Wang's resignation shall take effect on the commencement date of the term of office of the newly appointed independent non-executive Director.

Ms. Wang has confirmed that she has no disagreement with the Board and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and/or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board is pleased to announce that the Board has proposed to elect and appoint Mr. Xie Dong ("**Mr. Xie**") as an independent non-executive Director of the fourth session of the Board. The appointment of Mr. Xie shall be subject to the approval of the Shareholders at the general meeting of the Company.

The biographical details of Mr. Xie are as follows:

Mr. Xie Dong (謝東), aged 44. Mr. Xie has over 19 years of professional experience in sectors of financial management, auditing, investment and financing, and capital markets. He has served as the (i) chief financial officer and director of QuantaSing Group Limited (stock code: QSG) since January 2021 and June 2022, respectively; (ii) independent non-executive director of China BlueChemical Ltd. (中海石油化學股份有限公司) (stock code: 3983) since May 2021; and (iii) independent non-executive director of Duality Biotherapeutics, Inc. (stock code: 9606) since April 2025. Prior to these positions, from October 2006 to October 2007, Mr. Xie worked as a staff accountant in the auditing department of Ernst & Young Hua Ming LLP (安永華明會計師事務所(特殊普通合夥)). From April 2010 to September 2010, he served as vice president of CCB International (China) Limited (建銀國際(中國)有限公司). From October 2010 to August 2014, he served as associate director at Deloitte China. From September 2014 to December 2018, he served as the chief financial officer and company secretary of FinUp Finance Technology Group (Holding) Limited. From January 2019 to March 2020, he served as the director and chief financial officer of Renmai Technology Group (Holding) Limited (任買科技集團(控股)有限公司).

Mr. Xie obtained a bachelor's degree in economics and a master's degree in world economics from Nankai University in June 2003 and June 2006, respectively. He holds Chinese Institute of Certified Public Accountants (CICPA), Certified Internal Auditor (CIA), Certified Tax Agent (CTA) and Chinese Legal Professional Qualification.

Mr. Xie has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"); (ii) that he has no past or present financial or other interest in the business of the Group and has no connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence in acting as an independent non-executive Director at the time of his proposed appointment.

Mr. Xie will enter into a service contract with the Company for serving as an independent non-executive Director for a term commencing on the date of approval by the Shareholders of his appointment at the general meeting of the Company and ending on the earlier of (i) the third annual general meeting of the Company held after the date of his appointment, (ii) the expiry of the term of the current session of the Board, or (iii) the completion of three years from the date of his appointment. Mr. Xie will be entitled to a Director's fee of HKD220,000 per annum, which was recommended by the remuneration committee under the Board (the "**Remuneration Committee**") and has been determined with reference to the prevailing market conditions, his qualification and level of experience and his role.

Save as disclosed above, as at the date of this announcement, Mr. Xie (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any relationship with any Director, senior management or substantial or controlling Shareholders of the Company; (v) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vi) has no other matter that needs to be brought to the attention of the Shareholders.

ADJUSTMENT OF MEMBERS OF COMMITTEES UNDER THE BOARD

Due to the proposed changes of independent non-executive Director above, the Board has further resolved to adjust members of committees under the Board, with effect upon approval of Mr. Xie as independent non-executive Director by the Shareholders at the general meeting of the Company.

The member composition of the adjusted committees under the Board is set out as follows:

Audit Committee:

Chairman: Ms. Huang Suzhen
Members: Mr. Shu Yijie, Mr. Xie Dong

Nomination Committee:

Chairman: Mr. Yao Xue
Members: Mr. Shu Yijie, Ms. Huang Suzhen

The chairman and members of the Remuneration Committee remain unchanged.

PROPOSED CANCELLATION OF THE BOARD OF SUPERVISORS AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND CERTAIN RULES

In accordance with the Company Law of the People's Republic of China and other laws, regulations, regulatory provisions and relevant documents, and taking into account the actual situation of the Company to optimize the corporate governance structure, the Board has considered and approved the resolution to cancel the board of supervisors of the Company (the "**Board of Supervisors**"). The Audit Committee shall exercise the functions and powers of the Board of Supervisors as stipulated in the relevant laws and regulations and other regulatory documents.

Accordingly, the Board has considered and approved the proposed amendments (the "**Proposed Amendments**") to the Articles of Association of the Company (the "**Articles of Association**"), the Rules of Procedure of the Shareholders' General Meeting of the Company and the Rules of Procedure of the Board of Directors of the Company.

The proposed cancellation of the Board of Supervisors and the Proposed Amendments shall be subject to consideration and approval by the Shareholders at the general meeting of the Company. The Board further proposed the general meeting of the Company to authorize the Board and/or its authorized persons to have full authority to review and consider the content related to the Board of Supervisors or Supervisors in other rules and regulations of the Company and make appropriate amendments accordingly.

Upon such resolutions come into effect, the current members of the Board of Supervisors will cease to serve as Supervisors or hold any related positions in the Board of Supervisors, and Rules of Procedure of the Board of Supervisors of the Company will be abolished. All members of the Board of Supervisors of the Company have confirmed that they have no disagreement with the Board and there are no other matters relating to the Company's cancellation of the Board of Supervisors that need to be brought to the attention of the Shareholders and/or the Stock Exchange.

CLOSURE OF REGISTER OF MEMBERS

The Company further announces that the extraordinary general meeting of the Company (the "**EGM**") is proposed to be held on Friday, October 24, 2025.

In order to determine the list of the Shareholders entitled to attend and vote at the EGM, the register of members of the Company will be closed from Tuesday, October 21, 2025 to Friday, October 24, 2025 (both days inclusive), during which period no transfer of shares of the Company will be registered. To ascertain the Shareholders' entitlement to attend and vote at the EGM, all properly completed share transfer forms accompanied by the relevant share certificates must be lodged with the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (in respect of H Shareholders) or the Company's Board office at Room 5, 11/F and Rooms 601, 608-612, 6/F Huayin Building, No. 786 Minzhu Road, Zhongnan Road Sub-District, Wuchang District, Wuhan, Hubei Province, PRC (in respect of unlisted Shareholders), no later than 4:30 p.m. on Monday, October 20, 2025. Shareholders whose names appear on the register of members of the Company on Friday, October 24, 2025 are entitled to attend and vote at the EGM.

A circular and notice containing details of the resolutions to be proposed at the EGM will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.chinadzyl.com) and dispatched to the H Shareholders by means selected by the H Shareholders to receive the corporate communications in due course.

By order of the Board
Wuhan Dazhong Dental Medical Co., Ltd.
Mr. Yao Xue
Chairman and Executive Director

Wuhan, Hubei Province, PRC
September 26, 2025

As at the date of this announcement, the Board of the Company comprises: (i) Mr. Yao Xue, Ms. Shen Hongmin, Mr. Guo Jiaping and Ms. Liu Hongchan as executive Directors; and (ii) Mr. Shu Yijie, Ms. Huang Suzhen and Ms. Wang Taosha as independent non-executive Directors.